Axcella Announces Upcoming Investor Conference Presentation
A live audio webcast of this discussion will be available on the “Investors & News” section of the company’s website, www.axcellahealth.com, at
Internet Posting of Information
Axcella uses its website, www.axcellahealth.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the company’s website in the “Investors & News” section. Accordingly, investors should monitor this portion of the company’s website, in addition to its press releases,
About Axcella
Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions. The company’s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella’s pipeline includes lead therapeutic candidates for the reduction in risk of overt hepatic encephalopathy (OHE) recurrence and the treatment of non-alcoholic steatohepatitis (NASH). For more information, please visit www.axcellahealth.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005500/en/
Company Contact
jfredette@axcellahealth.com
857.320.2236
Source: Axcella